ch.oddb.org
 
Apotheken | Arzt | Interaktionen | Medikamente | MiGeL | Services | Spital | Zulassungsi.
N02CC03 - ZolmitriptanATC-DDD Version 2016. Source: WHO
N - Nervous System
 
N02 - Analgesics

This group comprises general analgesics and antipyretics.
All salicylic acid derivatives except combinations with corticosteroids (M01B) or opioids (N02AJ) are classified in N02BA - Salicylic acid and derivatives, as it is difficult to differentiate between the use of salicylates in rheumatic conditions and other therapeutic uses of salicylates.
All plain ibuprofen preparations are classified in M01A, even if they are only intended for use as pain relief.
There are a number of combined preparations, which contain analgesics and psycholeptics. These are classified in N02, as pain relief must be regarded as the main indication. Analgesics used for specific indications are classified in the respective ATC groups. E.g.:
A03D/
A03EA - Antispasmodic/psycholeptics/analgesic combinations
M01 - Antiinflammatory and antirheumatic products
M02A - Topical products for joint and muscular pain
M03 - Muscle relaxants
See comments to these groups.
Lidocaine indicated for postherpetic pain is classified in N01BB.

N02C - Antimigraine Preparations

This group comprises preparations specifically used in the prophylaxis and treatment of migraine. Analgesics, see N02A and N02B.
Beta blocking agents, see C07.
Antivertigo preparations, see N07.
Cyproheptadine, see R06A - Antihistamines for systemic use.
Tolfenamic acid, see M01AG - Fenamates.
Indometacin in combination with prochlorperazine and caffeine is classified in M01AB51 - Indometacin, combinations.
Botulinum toxin used in the prophylactic treatment of migraine is classified in M03AX01.

N02CC - Selective Serotonin (5ht1) Agonists
 

The DDDs for the selective serotonin (5HT1) agonists are based on the recommended initial dose in acute attacks of migraine.

N02CC03 - Zolmitriptan
StärkeAdm.RouteNote
2.5 mgN 
2.5 mgO 
2019 ©ywesee GmbH
Einstellungen | Hilfe | FAQ | Anmeldung | Kontakt | Home